Janux Therapeutics (NASDAQ:JANX) Trading 3.5% Higher

Janux Therapeutics, Inc. (NASDAQ:JANX) shares shot up 3.5% during trading on Thursday . The company traded as high as $45.00 and last traded at $44.97. 75,886 shares were traded during trading, a decline of 89% from the average session volume of 718,053 shares. The stock had previously closed at $43.45.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Scotiabank dropped their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $66.13.

Janux Therapeutics Trading Up 2.8 %

The stock has a fifty day moving average of $43.81 and a two-hundred day moving average of $44.67. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -35.61 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. The business had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. Janux Therapeutics’s quarterly revenue was up 709.1% compared to the same quarter last year. Equities analysts expect that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the transaction, the insider now directly owns 2,959,175 shares in the company, valued at $139,081,225. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the sale, the insider now owns 2,959,175 shares of the company’s stock, valued at approximately $139,081,225. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the completion of the sale, the chief executive officer now directly owns 307,054 shares in the company, valued at approximately $14,219,670.74. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 393,767 shares of company stock worth $17,857,979. Corporate insiders own 35.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in Janux Therapeutics by 82.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock worth $367,000 after buying an additional 4,400 shares during the last quarter. Capstone Investment Advisors LLC bought a new stake in Janux Therapeutics during the first quarter worth $1,969,000. Lester Murray Antman dba SimplyRich bought a new stake in Janux Therapeutics during the first quarter worth $300,000. ProShare Advisors LLC bought a new stake in Janux Therapeutics during the first quarter worth $251,000. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Janux Therapeutics during the first quarter worth $20,420,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.